HN 3392
Latest Information Update: 09 Jan 2008
At a glance
- Originator Hisamitsu Pharmaceutical
 - Class Anti-inflammatories; Antirheumatics; Small molecules
 - Mechanism of Action Cyclooxygenase inhibitors; Lipoxygenase inhibitors
 
- 
          
            
              Orphan Drug Status
              No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
 
Highest Development Phases
- Discontinued Inflammation; Rheumatic disorders